Coliseum Holdings I, LLC

SEC source: 0000899243-20-025337 · doc4.xml · derivative · entry 1

Coliseum Capital Management, LLC · CIK 0001409751 · Director · 10% owner

Shackelton Christopher S · CIK 0001430708 · Director · 10% owner

Coliseum Capital, LLC · CIK 0001409585 · Director · 10% owner

COLISEUM CAPITAL PARTNERS, L.P. · CIK 0001356974 · Director · 10% owner

Coliseum Capital Partners II, L.P. · CIK 0001567187 · Director · 10% owner

Coliseum Holdings I, LLC · CIK 0001678188 · Director · 10% owner

Coliseum Capital Co-Invest, L.P. · CIK 0001572285 · Director · 10% owner

Gray Adam · CIK 0001454123 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 444,944

Underlying: Common Stock · 7,659,339 shares

Expires not disclosed

F1 · derivative.exercise_price: The conversion rate in effect at any applicable time for conversion of each share of Series A Preferred Stock into common stock will be the quotient obtained by dividing the liquidation preference then in effect by the conversion price then in effect, plus cash in lieu of fractional shares. The initial liquidation preference is $100 per share and the initial conversion price is $3.33 per share.

F2 · derivative.exercise_date: When issued, the Series A Preferred Stock was immediately exercisable with respect to 1,214,791 shares of the Issuer's common stock (the "Common Shares"). The Series A Preferred Stock was convertible into 19,806,230 additional Common Shares only after Regulatory Approval (as such term is defined in the Certificate of Designations of the Series A Preferred Stock) has been obtained. The Series A Preferred Stock has no expiration date.

F3 · derivative.exercise_date: (Continued from Footnote 2) On September 14, 2020, Coliseum Holdings I LLC ("CHI"), the record owner of all 700,000 shares of Series A Preferred Stock of UTI (the "Preferred Shares") distributed the Preferred Shares to its four members, (a) Coliseum Capital Partners, L.P. ("CCP"), an investment limited partnership of which Coliseum Capital, LLC, a Delaware limited liability company ("CC"), is general partner and for which Coliseum Capital Management, LLC, a Delaware limited liability company ("CCM"), serves as investment adviser, (b) Coliseum Capital Partners II, L.P. ("CCP2"), an investment limited partnership of which CC is general partner and for which CCM serves as investment adviser, (c) Coliseum Capital Co-Invest, L.P. ("CCC" and, together with CCP and CCP2, the "Funds") and (d) a separate account investment advisory client of CCM (the "Separate Account").

F4 · derivative.exercise_date: (Continued from Footnote 3) Following this distribution, CCP2 and CCC distributed the Preferred Shares they received to their respective limited partners. We refer to these distributions as the "Distributions." Mr. Gray and his spouse, trusts established for the benefit of Mr. Gray's descendants, Mr. Shackleton, and trusts established for the benefit of Mr. Shackleton's descendants received Preferred Shares from each of CCP2 and CCC in their capacities as limited partners thereof.

F5 · derivative.exercise_date: (Continued from Footnote 4) Prior to the Distributions, CCM had voting and investment control over certain securities owned in the Separate Account. In connection with the Distribution, CCM and the client owner of the Separate Account amended the investment management account (the "Investment Management Account Amendment") to eliminate voting and dispositive authority over 56,000 shares of Series A Preferred Stock of UTI. As a result, the Reporting Persons disclaim beneficial ownership of such securities. Pursuant to the Investment Management Account Amendment, CCM retains voting and dispositive authority over 75,320 shares of Series A Preferred Stock of UTI held in the Separate Account.

F6 · derivative.exercise_date: (Continued from Footnote 5) Following the Distributions and the Investment Management Account Amendment, Mr. Gray and his trusts held 10,162 Preferred Shares; Mr. Shackleton and his trusts held 10,162 Preferred Shares; CCP held 349,300 Preferred Shares and the Separate Account held 75,320 Preferred Shares that are reported herein.

F7 · derivative.exercise_date: (Continued from Footnote 6) The Board of Directors of the Issuer has determined that, following the Distributions, as to the shares of Series A Preferred Stock held by the Reporting Persons, no Regulatory Approval is required prior to the Reporting Persons (A) converting a number of shares of Series A Preferred Stock into common stock provided that the number of shares of common stock issued pursuant to such conversion, in the aggregate, is less than or equal to 9.9% of the number of shares of common stock outstanding on an as converted basis on the date of the Distributions, and (B) voting a number of shares of Series A Preferred Stock provided that the voting power of such shares of Series A Preferred Stock and any shares of common stock issued upon conversion of such shares of Series A Preferred Stock is less than or equal to 9.9% of the voting power of the common stock on the date of the Distributions (the foregoing limitations, the "Continuing Caps").

F8 · derivative.exercise_date: (Continued from Footnote 7) Regulatory Approval will continue to be required for, and the Continuing Caps will remain in place with respect to, the shares of Series A Preferred Stock acquired by the Reporting Persons in the Distributions to the extent such shares, on an as converted basis, represent in excess of 9.9% of the Company's common stock and voting power as of the date of the Distributions.. The remaining shares of Series A Preferred Stock held by the Reporting Persons, which would be convertible into 8,052,142 Common Shares, remain subject to the Continuing Caps, and may not be converted or voted without receipt of Regulatory Approval or a further good faith determination by UTI that such Regulatory Approval is not required. The Reporting Persons have the right to request that such approval or a good faith determination that such approval is not required at any time.

F2 · derivative.expiration_date: When issued, the Series A Preferred Stock was immediately exercisable with respect to 1,214,791 shares of the Issuer's common stock (the "Common Shares"). The Series A Preferred Stock was convertible into 19,806,230 additional Common Shares only after Regulatory Approval (as such term is defined in the Certificate of Designations of the Series A Preferred Stock) has been obtained. The Series A Preferred Stock has no expiration date.

F3 · derivative.expiration_date: (Continued from Footnote 2) On September 14, 2020, Coliseum Holdings I LLC ("CHI"), the record owner of all 700,000 shares of Series A Preferred Stock of UTI (the "Preferred Shares") distributed the Preferred Shares to its four members, (a) Coliseum Capital Partners, L.P. ("CCP"), an investment limited partnership of which Coliseum Capital, LLC, a Delaware limited liability company ("CC"), is general partner and for which Coliseum Capital Management, LLC, a Delaware limited liability company ("CCM"), serves as investment adviser, (b) Coliseum Capital Partners II, L.P. ("CCP2"), an investment limited partnership of which CC is general partner and for which CCM serves as investment adviser, (c) Coliseum Capital Co-Invest, L.P. ("CCC" and, together with CCP and CCP2, the "Funds") and (d) a separate account investment advisory client of CCM (the "Separate Account").

F4 · derivative.expiration_date: (Continued from Footnote 3) Following this distribution, CCP2 and CCC distributed the Preferred Shares they received to their respective limited partners. We refer to these distributions as the "Distributions." Mr. Gray and his spouse, trusts established for the benefit of Mr. Gray's descendants, Mr. Shackleton, and trusts established for the benefit of Mr. Shackleton's descendants received Preferred Shares from each of CCP2 and CCC in their capacities as limited partners thereof.

F5 · derivative.expiration_date: (Continued from Footnote 4) Prior to the Distributions, CCM had voting and investment control over certain securities owned in the Separate Account. In connection with the Distribution, CCM and the client owner of the Separate Account amended the investment management account (the "Investment Management Account Amendment") to eliminate voting and dispositive authority over 56,000 shares of Series A Preferred Stock of UTI. As a result, the Reporting Persons disclaim beneficial ownership of such securities. Pursuant to the Investment Management Account Amendment, CCM retains voting and dispositive authority over 75,320 shares of Series A Preferred Stock of UTI held in the Separate Account.

F6 · derivative.expiration_date: (Continued from Footnote 5) Following the Distributions and the Investment Management Account Amendment, Mr. Gray and his trusts held 10,162 Preferred Shares; Mr. Shackleton and his trusts held 10,162 Preferred Shares; CCP held 349,300 Preferred Shares and the Separate Account held 75,320 Preferred Shares that are reported herein.

F7 · derivative.expiration_date: (Continued from Footnote 6) The Board of Directors of the Issuer has determined that, following the Distributions, as to the shares of Series A Preferred Stock held by the Reporting Persons, no Regulatory Approval is required prior to the Reporting Persons (A) converting a number of shares of Series A Preferred Stock into common stock provided that the number of shares of common stock issued pursuant to such conversion, in the aggregate, is less than or equal to 9.9% of the number of shares of common stock outstanding on an as converted basis on the date of the Distributions, and (B) voting a number of shares of Series A Preferred Stock provided that the voting power of such shares of Series A Preferred Stock and any shares of common stock issued upon conversion of such shares of Series A Preferred Stock is less than or equal to 9.9% of the voting power of the common stock on the date of the Distributions (the foregoing limitations, the "Continuing Caps").

F8 · derivative.expiration_date: (Continued from Footnote 7) Regulatory Approval will continue to be required for, and the Continuing Caps will remain in place with respect to, the shares of Series A Preferred Stock acquired by the Reporting Persons in the Distributions to the extent such shares, on an as converted basis, represent in excess of 9.9% of the Company's common stock and voting power as of the date of the Distributions.. The remaining shares of Series A Preferred Stock held by the Reporting Persons, which would be convertible into 8,052,142 Common Shares, remain subject to the Continuing Caps, and may not be converted or voted without receipt of Regulatory Approval or a further good faith determination by UTI that such Regulatory Approval is not required. The Reporting Persons have the right to request that such approval or a good faith determination that such approval is not required at any time.

F2 · ownership.nature: When issued, the Series A Preferred Stock was immediately exercisable with respect to 1,214,791 shares of the Issuer's common stock (the "Common Shares"). The Series A Preferred Stock was convertible into 19,806,230 additional Common Shares only after Regulatory Approval (as such term is defined in the Certificate of Designations of the Series A Preferred Stock) has been obtained. The Series A Preferred Stock has no expiration date.

F3 · ownership.nature: (Continued from Footnote 2) On September 14, 2020, Coliseum Holdings I LLC ("CHI"), the record owner of all 700,000 shares of Series A Preferred Stock of UTI (the "Preferred Shares") distributed the Preferred Shares to its four members, (a) Coliseum Capital Partners, L.P. ("CCP"), an investment limited partnership of which Coliseum Capital, LLC, a Delaware limited liability company ("CC"), is general partner and for which Coliseum Capital Management, LLC, a Delaware limited liability company ("CCM"), serves as investment adviser, (b) Coliseum Capital Partners II, L.P. ("CCP2"), an investment limited partnership of which CC is general partner and for which CCM serves as investment adviser, (c) Coliseum Capital Co-Invest, L.P. ("CCC" and, together with CCP and CCP2, the "Funds") and (d) a separate account investment advisory client of CCM (the "Separate Account").

F4 · ownership.nature: (Continued from Footnote 3) Following this distribution, CCP2 and CCC distributed the Preferred Shares they received to their respective limited partners. We refer to these distributions as the "Distributions." Mr. Gray and his spouse, trusts established for the benefit of Mr. Gray's descendants, Mr. Shackleton, and trusts established for the benefit of Mr. Shackleton's descendants received Preferred Shares from each of CCP2 and CCC in their capacities as limited partners thereof.

F5 · ownership.nature: (Continued from Footnote 4) Prior to the Distributions, CCM had voting and investment control over certain securities owned in the Separate Account. In connection with the Distribution, CCM and the client owner of the Separate Account amended the investment management account (the "Investment Management Account Amendment") to eliminate voting and dispositive authority over 56,000 shares of Series A Preferred Stock of UTI. As a result, the Reporting Persons disclaim beneficial ownership of such securities. Pursuant to the Investment Management Account Amendment, CCM retains voting and dispositive authority over 75,320 shares of Series A Preferred Stock of UTI held in the Separate Account.

F6 · ownership.nature: (Continued from Footnote 5) Following the Distributions and the Investment Management Account Amendment, Mr. Gray and his trusts held 10,162 Preferred Shares; Mr. Shackleton and his trusts held 10,162 Preferred Shares; CCP held 349,300 Preferred Shares and the Separate Account held 75,320 Preferred Shares that are reported herein.

F7 · ownership.nature: (Continued from Footnote 6) The Board of Directors of the Issuer has determined that, following the Distributions, as to the shares of Series A Preferred Stock held by the Reporting Persons, no Regulatory Approval is required prior to the Reporting Persons (A) converting a number of shares of Series A Preferred Stock into common stock provided that the number of shares of common stock issued pursuant to such conversion, in the aggregate, is less than or equal to 9.9% of the number of shares of common stock outstanding on an as converted basis on the date of the Distributions, and (B) voting a number of shares of Series A Preferred Stock provided that the voting power of such shares of Series A Preferred Stock and any shares of common stock issued upon conversion of such shares of Series A Preferred Stock is less than or equal to 9.9% of the voting power of the common stock on the date of the Distributions (the foregoing limitations, the "Continuing Caps").

F8 · ownership.nature: (Continued from Footnote 7) Regulatory Approval will continue to be required for, and the Continuing Caps will remain in place with respect to, the shares of Series A Preferred Stock acquired by the Reporting Persons in the Distributions to the extent such shares, on an as converted basis, represent in excess of 9.9% of the Company's common stock and voting power as of the date of the Distributions.. The remaining shares of Series A Preferred Stock held by the Reporting Persons, which would be convertible into 8,052,142 Common Shares, remain subject to the Continuing Caps, and may not be converted or voted without receipt of Regulatory Approval or a further good faith determination by UTI that such Regulatory Approval is not required. The Reporting Persons have the right to request that such approval or a good faith determination that such approval is not required at any time.

F9 · ownership.nature: Following the Distributions, Mr. Gray and his trusts held 10,162 Preferred Shares; Mr. Shackleton and his trusts held 10,162 Preferred Shares; CCP held 349,300 Preferred Shares and the Separate Account held 75,320 Preferred Shares that are reported herein.

SEC source: 0000899243-20-014228 · doc4.xml · nonDerivative · entry 1

Coliseum Capital Management, LLC · CIK 0001409751 · Director · 10% owner

Shackelton Christopher S · CIK 0001430708 · Director · 10% owner

Coliseum Capital, LLC · CIK 0001409585 · Director · 10% owner

COLISEUM CAPITAL PARTNERS, L.P. · CIK 0001356974 · Director · 10% owner

Coliseum Capital Partners II, L.P. · CIK 0001567187 · Director · 10% owner

Coliseum Holdings I, LLC · CIK 0001678188 · Director · 10% owner

Coliseum Capital Co-Invest, L.P. · CIK 0001572285 · Director · 10% owner

Gray Adam · CIK 0001454123 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.87 to $7.19, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission ("SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2 · ownership.nature: These securities were beneficially owned solely by Christopher Shackelton ("Shackelton") and consist of (a) 2,400 shares held directly by Shackelton, (b) 28,875 shares held by Shackelton's spouse and (c) 10,200 shares held by trusts for the benefit of Shackelton's descendants.

SEC source: 0000899243-19-029599 · doc4.xml · nonDerivative · entry 1

Coliseum Capital Management, LLC · CIK 0001409751 · 10% owner

Shackelton Christopher S · CIK 0001430708 · Director · 10% owner

Coliseum Capital, LLC · CIK 0001409585 · 10% owner

COLISEUM CAPITAL PARTNERS, L.P. · CIK 0001356974 · 10% owner

Coliseum Capital Partners II, L.P. · CIK 0001567187 · 10% owner

Coliseum Holdings I, LLC · CIK 0001678188 · 10% owner

Coliseum Capital Co-Invest, L.P. · CIK 0001572285 · 10% owner

Gray Adam · CIK 0001454123 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 0

F1 · kind: Sale of shares pursuant to an underwritten registered public offering.

F2 · ownership.nature: These securities sold were held directly by (a) Coliseum Capital Partners, L.P. ("CCP"), an investment limited partnership of which Coliseum Capital, LLC, a Delaware limited liability company ("CC"), is general partner and for which Coliseum Capital Management, LLC, a Delaware limited liability company ("CCM"), serves as investment adviser, (b) Coliseum Capital Partners II, L.P. ("CCP2" and, together with CCP, the "Funds"), an investment limited partnership of which CC is general partner and for which CCM serves as investment adviser, and (c) a separate account investment advisory client of CCM (the "Separate Account").

F3 · ownership.nature: Christopher Shackelton ("Shackelton") and Adam Gray ("Gray") are managers of and have an ownership interest in each of CCM and CC. Each of Shackelton, Gray, CCP, CCP2, the Separate Account, CC and CCM disclaims beneficial ownership of these securities except to the extent of that person's pecuniary interest therein.

F6 · ownership.nature: Following the transactions reported herein, CCP, CCP2 and the Separate Account each directly owned 0 shares of common stock.